Clinical trials: completed, in Iran
Moderate or Severe Nasolabial Folds
Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management
Rationale and background: Skin aging is a complex process that results in various changes in the skin, including wrinkles, sun spots, and sagging skin.
- Trial name
- NCT06509477
- Testing
- Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.), Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)
- Where
- Iran
- Volunteers
- 104 people
- Sponsor
- Espad Pharmed
Flank Fat
Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat
Flank region fat is a factor affecting beauty that makes people feel uncomfortable about themselves. In 2015, deoxycholic acid was approved by the American FDA for treatment of flank fat.
- Trial name
- NCT07004010
- Testing
- Deoxycholic Acid Injection
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed
Submental Fullness
Effectiveness and Safety Evaluation of Embella (Deoxycholic Acid, by Espad Pharmed Co.) in Management of Submental Fat
Submental fat (SMF) is a factor affecting beauty that makes people feel uncomfortable about themselves. In 2015, deoxycholic acid with the brand name KYBELLA® was approved by the American FDA for treatment of submental fat.
- Trial name
- NCT06509438
- Testing
- Embella (Deoxycholic acid, produced by Espad Pharmed Co.)
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Espad Pharmed
Type 3 Von Willebrand's Disease
Type 3 Von Willebrand International Registries Inhibitor Prospective Study
International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand…
- Trial name
- 3WINTERS-IPS (NCT02460458)
- Testing
- Von Willebrand Factor
- Where
- 25 sites in Finland, France and 8 more
- Volunteers
- 265 people
- Sponsor
- Fondazione Angelo Bianchi Bonomi
Dexamethasone, Pregnancy
Effect of Dexamethasone on Labor Induction
Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the a statistician did coding to identify groups of users of pill A or pill…
- Trial name
- NCT05070468
- Testing
- Dexamethasone 0.5mg
- Where
- Iran
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Alborz Medical University
HER2-positive Breast Cancer
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
This study was a phase III, multicenter, triple-blind, equivalency clinical trial to determine the therapeutic efficacy and safety between Pertuzumab® (CinnaGen Co.) compared to originator pertuzumab in HER2-positive early breast…
- Trial name
- NCT04957212
- Testing
- Trastuzumab, Pertuzumab, Carboplatin
- Where
- 44 sites in Iran
- Volunteers
- 214 people
- Sponsor
- Cinnagen
Malignant Neoplasm of Breast
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab in…
- Trial name
- NCT03425656
- Testing
- Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
- Where
- 19 sites in Iran
- Volunteers
- 108 people
- Sponsor
- AryoGen Pharmed Co.
Epilepsy, Idiopathic Generalized
Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
This study is an open-label, active-controlled,non-inferiority trial comparing efficacy and safety of levetiracetam versus valproate in idiopathic generalized tonic-clonic epilepsy.
- Trial name
- NCT03940326
- Testing
- Levetiracetam, Valproate
- Where
- Iran
- Volunteers
- 103 people
- Sponsor
- Mazandaran University of Medical Sciences
Vitamin D Deficiency, Cardiomyopathies
Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
Background and study aim: Heart diseases are among the most common causes of death worldwide. A large proportion of deaths are caused by heart attacks (myocardial infarction), where blood flow to the heart is reduced resulting in…
- Conditions
- Vitamin D Deficiency, Cardiomyopathies, Apoptosis, Inflammation
- Trial name
- NCT04323852
- Testing
- Vitamin D
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
COVID-19
Colchicine Plus Phenolic Monoterpenes to Treat COVID-19
In this randomized controlled clinical trial, defined cases of COVID-19 with mild, moderate, or severe pneumonia (according to the NIH guideline) were treated with conventional treatment regimens (controls) as well as in…
- Trial name
- NCT04392141
- Testing
- Standard Treatment, Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
- Where
- Iran
- Volunteers
- 120 people
- Sponsor
- Kermanshah University of Medical Sciences
Active Rheumatoid Arthritis
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
The purpose of this study is to compare the efficacy and safety of adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis.
- Trial name
- NCT03172325
- Testing
- Adalimumab, Methotrexate, Folic Acid
- Where
- 10 sites in Iran
- Volunteers
- 136 people
- Sponsor
- Cinnagen
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation.
- Trial name
- NCT03288987
- Testing
- Bevacizumab + FOLFIRI-3
- Where
- 22 sites in Iran
- Volunteers
- 126 people
- Sponsor
- AryoGen Pharmed Co.
Congenital Fibrinogen Deficiency
Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.
- Trial name
- NCT02267226
- Testing
- Octafibrin
- Where
- 12 sites in United States, Bulgaria and 7 more
- Volunteers
- 25 people
- Sponsor
- Octapharma
Congenital Fibrinogen Deficiency
Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency
This study will assess the efficacy of Octafibrin, a fibrinogen concentrate in in the on-demand treatment of spontaneous or traumatic bleeding episodes in paediatric patients less than 12 years of age.The planned study duration…
- Trial name
- NCT02408484
- Testing
- Octafibrin
- Where
- 4 sites in India, Iran and 1 more
- Volunteers
- 15 people
- Sponsor
- Octapharma
Neuromyelitis Optica Spectrum Disorder
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
The purpose of this study is to compare annual relapse rate, expanded disability status scale, and side effects of azathioprine and rituximab in patients with neuromyelitis optica spectrum disorder during a one year follow up…
- Trial name
- NCT03002038
- Testing
- Azathioprine, Rituximab
- Where
- Iran
- Volunteers
- 86 people
- Sponsor
- Isfahan University of Medical Sciences
Multiple Sclerosis
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
The purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis
- Trial name
- IMPAMS (NCT01214317)
- Testing
- plasmapheresis
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Isfahan University of Medical Sciences
Surgical Blood Loss, Third Molar
Effect of Warm Saline Irrigation on Bleeding in Mandibular Third Molar Surgery
The objective of this research is to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
- Trial name
- NCT04143373
- Testing
- warm saline irrigation
- Where
- Iran
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Androgenetic Alopecia
Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
The purpose of this study is evaluating the efficacy and safety of a topical herbal solution in males for the treatment of Androgenetic alopecia.
- Trial name
- NCT03753113
- Testing
- Topical Herbal Solution, Topical Minoxidil 5%
- Where
- Iran
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Farid Masoud
Anemia in End-Stage Renal Disease
Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
This Phase III, randomized, two-armed, parallel, double-blind, active-controlled clinical trial is designed to compare efficacy and safety of CinnaPoietin® (Beta erythropoietin) and Eprex® (epoetin alpha) on the treatment of…
- Trial name
- NCT03408639
- Testing
- CinnaPoietin®, Eprex®, Nephrovit
- Where
- 8 sites in Iran
- Volunteers
- 156 people
- Sponsor
- Cinnagen
Diffuse Large B-cell Lymphoma
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma
This is a multicenter, double-blind, randomized study comparing the efficacy, pharmacokinetics (PK)/pharmacodynamics (PD), safety and immunogenicity profile of RTXM83 (rituximab biosimilar) vs reference rituximab (MabThera®)…
- Trial name
- NCT02268045
- Testing
- RTXM83, Mabthera
- Where
- 87 sites in Argentina, Brazil and 10 more
- Volunteers
- 272 people
- Sponsor
- mAbxience Research S.L.